Wall Street analysts expect Calithera Biosciences Inc (NASDAQ:CALA) to post ($0.33) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have issued estimates for Calithera Biosciences’ earnings, with the lowest EPS estimate coming in at ($0.41) and the highest estimate coming in at ($0.21). Calithera Biosciences reported earnings per share of ($0.15) during the same quarter last year, which suggests a negative year over year growth rate of 120%. The firm is scheduled to report its next earnings report on Tuesday, August 14th.
According to Zacks, analysts expect that Calithera Biosciences will report full-year earnings of ($1.40) per share for the current fiscal year, with EPS estimates ranging from ($1.65) to ($1.00). For the next financial year, analysts anticipate that the business will post earnings of ($1.70) per share, with EPS estimates ranging from ($2.38) to ($1.00). Zacks’ earnings per share averages are a mean average based on a survey of research firms that that provide coverage for Calithera Biosciences.
Calithera Biosciences (NASDAQ:CALA) last posted its earnings results on Thursday, May 10th. The biotechnology company reported ($0.37) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.32) by ($0.05). Calithera Biosciences had a negative net margin of 131.51% and a negative return on equity of 22.92%. The firm had revenue of $5.19 million for the quarter, compared to analysts’ expectations of $7.28 million.
NASDAQ:CALA traded down $0.40 during midday trading on Friday, reaching $4.30. 518,103 shares of the stock traded hands, compared to its average volume of 488,949. The stock has a market capitalization of $173.85 million, a price-to-earnings ratio of -5.47 and a beta of 2.53. Calithera Biosciences has a 12-month low of $4.30 and a 12-month high of $20.05.
Large investors have recently added to or reduced their stakes in the company. Jane Street Group LLC acquired a new stake in shares of Calithera Biosciences in the fourth quarter worth $103,000. Sofinnova Ventures Inc acquired a new stake in shares of Calithera Biosciences in the first quarter worth $126,000. Lazard Asset Management LLC acquired a new stake in shares of Calithera Biosciences in the fourth quarter worth $167,000. Ellington Management Group LLC acquired a new stake in shares of Calithera Biosciences in the fourth quarter worth $191,000. Finally, Citigroup Inc. increased its stake in shares of Calithera Biosciences by 78.4% in the first quarter. Citigroup Inc. now owns 23,746 shares of the biotechnology company’s stock worth $150,000 after acquiring an additional 10,433 shares during the period. Hedge funds and other institutional investors own 62.82% of the company’s stock.
About Calithera Biosciences
Calithera Biosciences, Inc, a clinical-stage bio-pharmaceutical company, focuses on the discovery and development of small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer in the United States. Its lead product candidate is CB-839, an inhibitor of glutaminase, which is in Phase II clinical trial to treat solid tumors.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Calithera Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calithera Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.